Bortezomib-Dexamethasone-Doxorubicin-Study

Sponsor

Austrian Forum Against Cancer (Other)

Overall Status

Completed

CT.gov ID

NCT00401804

Collaborator

(none)

Enrollment

Locations

Duration (Months)

Patients Per Site

0.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The primary objective of the study is to evaluate the activity of BDD in subjects with acute renal failure as measured by· reversal of acute renal failureSecondary objectives· tumor response (complete and partial response)· To evaluate the safety of Bortezomib- Doxorubicin-Dexamethasone in this patient population· to evaluate the activity of Bortezomib- Doxorubicin -Dexamethasone on progression free survival · to evaluate the activity of Bortezomib- Doxorubicin -Dexamethasone on overall survival

Condition or Disease	Intervention/Treatment	Phase
Multiple Myeloma Renal Insuficiency	Drug: Dexamethasone, Bortezomib, Doxorubicin	Phase 2

Study Design

Study Type:

Interventional

Actual Enrollment :

72 participants

Allocation:

Non-Randomized

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Bortezomib-Doxorubicin-Dexamethasone as Treatment for Patients With Multiple Myeloma Presenting With Acute Renal Failure

Study Start Date :

Feb 1, 2006

Actual Primary Completion Date :

Nov 1, 2008

Actual Study Completion Date :

Nov 1, 2009

Outcome Measures

Primary Outcome Measures

OS []

Secondary Outcome Measures

OR []

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Confirmed diagnosis of multiple myeloma ·
Acute multiple myeloma related renal failure (Diagnosis established by clinical and laboratory findings including renal biopsy - if indicated)a) Newly diagnosed patients:Decrease of GFR to < 50ml/minb) Previously treated patients with GFR of ≥ 60ml/min within last 4 weeks: decrease in GFR > 25% and to < 60ml / min,concomitantly with either increase in paraproteins (>25%) and/or decrease in hemoglobin ≥ 2 g/dl (within 4 weeks) and/or increase in bone marrow plasma infiltration and/or increase in number of bone lesions and/or hypercalcaemia (Ca > 11.5 mg/dl or 2.8 mmol/l) as signs of disease progression·
Age > 20 years·
ECOG performance status of ≤ 3.·
Platelet count > 50.000/µl·
WBC > 2000/µl·
Total bilirubin < 1.5 x upper limit of normal,
AST, ALT < 2.5 x upper limit of normal·
International Normalized Ratio (INR) < 1.5; APTT < 1.5 x upper limit of normal·
Fertile women and men of childbearing potential (<2 years after last menstruation in women) must use effective means of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgically sterile)· Negative serum or urine β-HCG pregnancy test at screening for subjects of child-bearing potential·
Patient's written informed consent

Exclusion Criteria:

History of malignancy other than squamous cell carcinoma, basal cell carcinoma of the skin or carcinoma in situ of the cervix within the last 5 years.·
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start, or anticipation of the need for major surgical procedure during the course of the study.·
Evidence of CNS involvement or spinal cord compression.·
Neuropathy Grade ≥ 2·
A history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant and adversely affecting compliance to study drug.·
NYHA Status > 2, i.e. clinically significant cardiac disease, (congestive heart failure, symptomatic coronary artery disease, cardiac arrhythmias, and arterial hypertension not well controlled with medication) or myocardial infarction within the last 6 months ·
Evidence of bleeding diathesis or coagulopathy·
Serious, non-healing wound or ulcer·
Evidence of any severe active acute or chronic infection.·
Evidence of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or patient at high risk from treatment complications·
Patient is known to be HIV-positive, Hbs-antigen positive or HCV-RNA-positive·
Pregnant women or nursing mothers·
Have received bortezomib within 4 weeks before enrollment·
Half body irradiation < 28 days before enrollment·
Has known or suspected hypersensitivity or intolerance to boron, mannitol, or heparin, if an indwelling catheter is used

Contacts and Locations

Locations

	Site	City	Country	Postal Code
1	Landeskrankenhaus Feldkirch	Feldkirch	Austria
2	Klinischen Abteilung für Hämatologie, Medizinische Universitätsklinik Graz	Graz	Austria	8036
3	Landeskrankenhaus Leoben	Leoben	Austria
4	Dep. of Internal Medicine I, Oncology, SALK - Gemeinnützige Salzburger Landeskliniken	Salzburg	Austria	5020
5	Medical University of Vienna, Dep. of Internal Medicine I	Vienna	Austria	1090
6	Universitätsklinik für Innere Medizin I	Vienna	Austria	1090
7	Wilhelminenspital Vienna, 1st Med. Department - center for Oncology and Hematology	Vienna	Austria	1160
8	Klinikum Kreuzschwestern Wels GmbH	Wels	Austria	4600
9	FN Brno Interni Hematoonkolog. klinika	Brno	Czech Republic	62500

Sponsors and Collaborators

Austrian Forum Against Cancer

Investigators

Principal Investigator: Heinz Ludwig, MD, Univ.Prof., Austrian Forum agianst Cancer; Wilhelminenspital Vienna, 1st. Med. Department - center for Oncology and Hematology